Abu-Sbeih et al. observed higher cholecystitis risk with anti-CTLA-4 monotherapy or combination therapy (40% of 25 cases) compared to anti-PD-1/PD-L1 monotherapy (60%) (Boike and Dejulio, 2017). This evidence concerns the gene CTLA4 and Cholecystitis.